After securing more than EUR 4 million of private and public funding in 2019, a:head today closed another 7-digit EUR equity round with a consortium of investors including red stars.com data AG, the company’s seed investor.

a:head bio AG today announced a long-term partnership with the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria for the development of next generation central nervous system (CNS) therapeutics and the award of an Early Stage grant from the Austrian Research Promotion Agency (FFG)

a:head bio AG, an Austrian biotech company focusing on the development of next generation therapeutics for the treatment of brain disorders based on human cerebral organoids has recently been incorporated.